|
|
Post by mindovermatter on Jan 26, 2016 15:46:33 GMT -5
This is FUD. The quote is "Mannkind is working with investment bankers on options". That doesn't mean the company is up for sale. Matt would be crazy to not explore all the options for raising funds. But, anyone thinking Al wants out has a greater than 99% chance of being wrong. This isn't an "article" this its a rumor. The fact this story is out and out by Reuters is not by mistake. The company is up for sale. The question now is whether or not it will get a reasonable sales price that will get the nod from Al. |
|
|
|
Post by compound26 on Jan 26, 2016 15:47:03 GMT -5
Just spitballin' here but is everyone ok with a 1 for 1 in Berkshire A shares? (Apologies to Warren as i feel i must) I am fine with B shares.  |
|
|
|
Post by nylefty on Jan 26, 2016 15:47:11 GMT -5
Stock manipulation is illegal also and we've all seen how that is enforced. It's not a matter of some government agency "enforcing" the copyright law. Reuters could go to civil court and sue for copyright infringement. Wouldn't be the first time a big media company has done so. |
|
|
|
Post by madog365 on Jan 26, 2016 15:49:41 GMT -5
The biggest question nobody asked: Who leaked this after the boardroom meeting and why? Somebody who wants mannkind sold for peanuts and afrezza buried. |
|
|
|
Post by LosingMyBullishness on Jan 26, 2016 15:58:27 GMT -5
Someone bought >150k shares at about 14:31 for about 0.98. Wonder when that meeting was finished.
|
|
|
|
Post by kc on Jan 26, 2016 16:01:18 GMT -5
This is FUD. The quote is "Mannkind is working with investment bankers on options". That doesn't mean the company is up for sale. Matt would be crazy to not explore all the options for raising funds. But, anyone thinking Al wants out has a greater than 99% chance of being wrong. This isn't an "article" this its a rumor. The fact this story is out and out by Reuters is not by mistake. The company is up for sale. The question now is whether or not it will get a reasonable sales price that will get the nod from Al. This story was out on the Day the SNY termination was announced it was on the Dow Jones Wire service.
DOW JONES & COMPANY, INC. 10:05 AM ET 1/5/2016
Symbol Last Price Change
MNKD 1.05down -0.4 (-27.59%)
SNY 42.23down +0.03 (+0.07%)
QUOTES AS OF 11:05:27 AM ET 01/05/2016
MannKind Corp. (MNKD) on Tuesday announced the termination of its licensing pact with Sanofi-Aventis in the U.S. for the development and sale of its inhaled diabetes medicine Afrezza and signaled that it might look to sell the drug.
Shares of the company tumbled 28% in early trading. Over the past three months, shares have dropped 67%, including Tuesday's decline.
MannKind (MNKD) said that it and Sanofi(SNY) would begin transition talks to return Afrezza to MannKind(MNKD) over the next three to six months, with the termination effective no later than July 4. As a result of squashed deal, MannKind(MNKD) said it is reviewing its strategic options for Afrezza. The evaluation of options typically include a full or partial sale.
The company struck the marketing deal with French drug company Sanofi(SNY) in August 2014. In its most recent quarterly earnings call with analysts and investors, then-Chief Executive Hakan Edstrom said MannKind(MNKD) was "disappointed with the growth of Afrezza sales during the first nine months of the year," pointing to insurance reimbursement issues and slow uptake. Mr. Edstrom stepped down as CEO in November.
Write to Lisa Beilfuss at lisa.beilfuss@wsj.com
(END) Dow Jones Newswires
01-05-161105ET
Copyright (c) 2016 Dow Jones & Company, Inc
Read more: mnkd.proboards.com/user/284/recent#ixzz3yO2xyIrO
|
|
|
|
Post by lakers on Jan 26, 2016 16:08:23 GMT -5
Post from Yahoo: finance.yahoo.com/news/insulin-drug-maker-mannkind-explores-195258110.html
NEW YORK, Jan 26 (Reuters) - Mannkind Corp, the U.S. maker of inhaled insulin drug Afrezza, is exploring strategic options, including the sale of itself, people familiar with the matter said on Tuesday.
Mannkind is working with investment bankers on options, the people said, asking not to be identified because the deliberations are confidential. Mannkind did not respond to requests for comment.
Mnkd has $1.6B tax loss carry forward and $725 remaining milestone bonus it can potentially get from Sanofi via settlement. If Mnkd is acquired for $2.3B, $5.5/share, the acquirer still gets the whole company for free. Got it?
Dearfield forced DNDN to sell the co.
|
|
|
|
Post by bradleysbest on Jan 26, 2016 16:10:20 GMT -5
What a shame if sold for 2.3 B...... years invested for no return on investment!
|
|
|
|
Post by seanismorris on Jan 26, 2016 16:16:07 GMT -5
If a deal gets done, it would more likely involve something creative - like splitting the company into two or three and selling off none core assets.
In my mind the Core asset is TS. And, Matt would remain the CEO of that company.
Whatever they come up with would have to raise some serious funds and significantly dilute Al's shares (control).
|
|
|
|
Post by scottiemac on Jan 26, 2016 16:24:02 GMT -5
Seeing as BRK-A closed at $189,640.00 a share today, I'm down with that, lol. Even BRK-B closed at $125.89 which is also not bad.
|
|
|
|
Post by chuck on Jan 26, 2016 16:35:33 GMT -5
Post from Yahoo: finance.yahoo.com/news/insulin-drug-maker-mannkind-explores-195258110.html NEW YORK, Jan 26 (Reuters) - Mannkind Corp, the U.S. maker of inhaled insulin drug Afrezza, is exploring strategic options, including the sale of itself, people familiar with the matter said on Tuesday. Mannkind is working with investment bankers on options, the people said, asking not to be identified because the deliberations are confidential. Mannkind did not respond to requests for comment. Mnkd has $1.6B tax loss carry forward and $725 remaining milestone bonus it can potentially get from Sanofi via settlement. If Mnkd is acquired for $2.3B, $5.5/share, the acquirer still gets the whole company for free. Got it? Dearfield forced DNDN to sell the co. Loss carryforward has little if any value in a buyout situation. This is well known to anyone doing M&A due to restrictions in use of NOL's after change in control. Mnkd will get zero of the $725m as the conditions for payment were never met and sny holds no obligation settle anything. Likely investment bankers will shop this around and receive no bid if they put out a floor of $1 bid price, just like what happened with DNDN. This is cruel to shareholders to give false hope of billion dollar bailouts. |
|
|
|
Post by staypuft on Jan 26, 2016 16:39:06 GMT -5
Not sure if anyone's noticed yet, but for people writing to MNKD on Twitter, MNKD's response has been that "Mannkind will announce an investor call soon & will answer as many questions from Twitter & Facebook as possible. Thank you."
Been in MNKD for about 2 years now and have always been a fan of their technosphere technology. Hoping for the best for all.
|
|
|
|
Post by bioexec25 on Jan 26, 2016 16:43:22 GMT -5
Not sure if anyone's noticed yet, but for people writing to MNKD on Twitter, MNKD's response has been that "Mannkind will announce an investor call soon & will answer as many questions from Twitter & Facebook as possible. Thank you."
Been in MNKD for about 2 years now and have always been a fan of their technosphere technology. Hoping for the best for all.
Thanks. Btw, your board name named after the product or a ghostbuster reference? |
|
|
|
Post by esstan2001 on Jan 26, 2016 16:43:33 GMT -5
The rumor can be a tool to drive some short covering. Why hold if there may be a higher, possibly multi-dollar offer that you are then forced to cover at.
|
|
|
|
Post by smwill77 on Jan 26, 2016 16:49:34 GMT -5
Post from Yahoo: finance.yahoo.com/news/insulin-drug-maker-mannkind-explores-195258110.html NEW YORK, Jan 26 (Reuters) - Mannkind Corp, the U.S. maker of inhaled insulin drug Afrezza, is exploring strategic options, including the sale of itself, people familiar with the matter said on Tuesday. Mannkind is working with investment bankers on options, the people said, asking not to be identified because the deliberations are confidential. Mannkind did not respond to requests for comment. Mnkd has $1.6B tax loss carry forward and $725 remaining milestone bonus it can potentially get from Sanofi via settlement. If Mnkd is acquired for $2.3B, $5.5/share, the acquirer still gets the whole company for free. Got it? Dearfield forced DNDN to sell the co. Loss carryforward has little if any value in a buyout situation. This is well known to anyone doing M&A due to restrictions in use of NOL's after change in control. Mnkd will get zero of the $725m as the conditions for payment were never met and sny holds no obligation settle anything. Likely investment bankers will shop this around and receive no bid if they put out a floor of $1 bid price, just like what happened with DNDN. This is cruel to shareholders to give false hope of billion dollar bailouts. [ Yes it is, cruel. Yet he continues to serve as this boards "paste and waste" by repeating links any of us can easily find on the main financial sites, then adding some obscure, overly confusing blurb at the end like he's trying to give highly intelligent "clues" to what he's witnessing behind closed doors. But because the clues are positive in nature in lieu of negative (bashing) our mods just let it go. Go ahead and ban me for continually calling out Lakers on his games, but if you ban me perhaps you should ask Lakers should suffer the same fate? |
|
